• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

3v.org

Venture Capital Matters

  • Pitch a Startup
    • Make a Contribution
  • Market Reports
  • Technologies
    • Technology Events
  • Domain Names for Startups
  • About
    • How to raise venture capital
    • How to raise seed funding from angel investors
    • How private equity and venture capital firms operate
    • What is the difference between private equity and VC funding?
    • What technology trends are considered hot among VC firms?
    • What is elevator pitch?
    • What is startup burn rate?
    • Does failure to launch a startup spell the end of the entrepreneur’s ambitions?
    • How to avoid pitfalls in founding a startup
    • Why do startups fail?
    • What are the traits of successful startup founder?
    • What are startup vanity metrics?
    • Why investing in the next generation of women and diverse entrepreneurs is a crucial part to the success of the tech infrastructure
    • Where are VCs seeing opportunity
    • How do startup valuations work?
    • What is startup accelerator?
    • How to scale an early-stage startup team, how much to pay and how to distribute equity
    • Don’t mix business with friendship: when it comes to building a founding team for a startup, this adage may not always apply
    • What is a social unicorn?
    • Secure Your Startup’s Future: The Importance of Succession Planning
  • Contact

Kineta Secures $1.8 Million Funding on Positive Phase 1a Clinical Study Results with LHF-535

August 6, 2019 By admin Leave a Comment

Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense, announced today that it secured a $1.8 million Translation Fund Award supplement from the Wellcome Trust based on the positive Phase 1a clinical study results in healthy volunteers. This award will fund the Phase 1b multiple ascending dose (MAD) clinical trial and position LHF-535 for Phase 2 evaluation in Lassa fever patients where no approved treatment is currently available. The Wellcome Trust awarded Kineta with a Translation Fund Award of up to $7.2M in 2016 to advance the development of LHF-535 for the treatment of Lassa fever.

“We are encouraged by the favorable safety and pharmacokinetic data from the Phase 1a study that supports the continued development of LHF-535 as a potential oral treatment for patients with Lassa fever,” said Kineta CEO Shawn Iadonato. “The Wellcome Trust has been very supportive of our Lassa fever program and their continued support is further validation of this novel drug program.”

A phase 1a clinical study was conducted to evaluate the safety and pharmacokinetic profile of LHF-535 in healthy volunteers. A total of 48 volunteers across six cohorts were evaluated in a double-blind, placebo-controlled study. Each participant received a single oral dose of either placebo or active LHF-535 across six doses ranging from 0.3 to 40 mg per kg of body weight.

LHF-535 was safe and well tolerated with the frequency of treatment-related adverse events being similar across placebo and active LHF-535 participants with no dose relationship pattern. There was one moderate (grade 2) treatment-related treatment emergent adverse event, while all others were mild (grade 1). LHF-535 pharmacokinetics assessment demonstrated exposures predicted to be clinically efficacious.

A Phase 1b multiple ascending dose clinical trial will be initiated in Q3 2019 to further evaluate the safety and pharmacokinetic profile of LHF-535 in healthy volunteers. Earlier this year, Kineta announced that it received a grant of up to $5.8M from the National Institute of Allergy and Infectious Diseases (NIAID) to expand LHF-535 into additional potential arenavirus indications.

Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. We have leveraged our expertise in immunology to advance a focused pipeline of investigational drugs in oncology, neuroscience and biodefense. We actively collaborate with a broad array of private, government and industry partners to advance our innovative products. For more information on Kineta visit our website, www.kinetabio.com, follow us on Twitter at @kinetabio, LinkedIn and Like us on facebook.com/KinetaBio.

Lassa fever is an acute viral illness that is known to be endemic in West Africa. NIAID and CDC have identified it as a Category A pathogen that poses the highest risk to national security and public health. Lassa fever causes 100,000-300,000 infections and is responsible for ~5000 deaths annually in West Africa. Death rates are particularly high for women in the third trimester of pregnancy and fetal loss occurs in nearly all infected pregnant women. There is a significant unmet medical need as there are currently no therapeutics or vaccines that are indicated to treat Lassa fever.

LHF-535 is a first-in-class antiviral treatment with potent activity against Lassa and other arenaviruses. It inhibits virus entry into target host cells and serves to suppress viral replication. It has demonstrated safety and efficacy in preclinical models. In preclinical studies, LHF-535, reduced virus titers and provided complete survival when administered as a therapeutic in animals infected with Lassa. LHF-535 is a once daily oral therapeutic currently being evaluated in first-in-human Phase 1 safety studies. Kineta is receiving funding from the Wellcome Trust to advance LHF-535 through Phase I human safety studies and the National Institutes of Health to investigate broad activity against arenaviruses.

SOURCE Kineta, Inc.

Filed Under: PR

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

The Immersive Experience in the Museum World
How insurers thrive in a turbulent market
Leveraging Artificial Intelligence to Drive Cost Savings and Productivity in Uncertain Times
The shipping industry is undergoing a significant change with the influx of new vessels arriving just as the growth of trade is beginning to slow down
Climate change is increasingly affecting the production of beer ingredients
Unfulfilled Dreams: The Aftermath of China’s Stalled Real Estate Developments
Huawei on the Brink: Biden Administration Considers Cutting Off the Tech Giant”

Market Research Media

Streaming video, training, and gaming coming together to form a cohesive and diverse media and entertainment ecosystem
Turn Your Story into a Game: The Art of Gamifying Your Plot
The end of cheap money is redrawing the map of corporate earnings
The Future of Virtual Reality: How VR is Changing Industries
Market Research Media Survey: The State of Streaming Services
Media measurement services provide a holistic view of cross-media consumption
Gen Z ranks top in luxury sales

Secondary Sidebar

Technologies

The use of immersive technology in museums is still in its early stages
The low tech unemployment rate and hiring activity confirms the long-term demand for tech talent
Virgin Orbit and SatRev Sign Launch Services Agreement
Harnessing the Power of Innovation for a Better Tomorrow
Breaking Down Silos: The Need for Cross-Sector Collaboration in Tackling Global Challenges

Tech Events

Embedded World 2023, March 14-16, 2023, Nuremberg, Germany
The IOT Solutions World Congress and Barcelona Cybersecurity Congress, May 21-23, 2024, Fira de Barcelona’s Gran Via venue
React Summit 2023, June 2 (in-person in Amsterdam) & June 6 (remote), 2023
Blockchaining 2023: The crypto world is facing a crisis of confidence
ScyllaDB Summit 2023 taking place online on February 15-16, 2023

Footer

Recent Posts

  • Gradient, a company specializing in eco-friendly heating and cooling solutions, has raised $18 million in a Series A funding round
  • The Importance of Diversity and Inclusion in the Workplace
  • Sequoia Capital announces its $195 Mln dedicated seed fund
  • Sublime Systems Secures $40 Million Series A to Electrify and Scale Decarbonized Cement Production
  • actyv.ai Raises Pre-Series A Funding to Fuel Global Expansion, Product Enhancement
  • Ottopia announces $14.5M Series A Funding Round
  • LSE launches £50m accelerator for “social unicorns”
  • Blues Wireless Raises $32M To Accelerate Enterprise Adoption of Cellular IoT
  • How Artificial Intelligence May Affect Professional Photography
  • Introducing the $60M Axelar Ecosystem Startup Funding Program

Dossier

Goodyear to Acquire Cooper, Creating Stronger U.S.-Based Leader in Global Tire Industry
Defense Market, July 2022
Hippo Appoints Richard McCathron as Chief Executive Officer
Carrefour and Tesco Agree Not to Extend Alliance
Intalio Acquires Nyxeia

Press Media Release

HR Maven Tom Painter Joins System High as Vice President of Human Capital
FTX, Tom Brady & Gisele Bündchen Announce Long-Term Partnership
Exclusive.org Announces Sale of Exclusive Domains
Clarivate Names World’s Leading Journals with the 2022 Journal Citation Reports
PUBLIC SERVICES INTERNATIONAL LAUNCHES INTERACTIVE DOCUMENTARY EXPERIENCE ON GLOBAL HEALTH WORKERS

App Coding

Cybertech 2023 in Tel Aviv: Navigating the Challenges of App Security
New app to help northeastern Illinois drivers avoid traffic and earn rewards for improving their commute
Brits app-sessed: New Builder.ai data reveals over 20 million can't live without social media apps
A developer’s job isn't just to churn out code every day
Scrub your code in real-time

API Coding

Profound Logic Builds IBM i Salesforce API Integration Example without Writing a Single Line of Code
How to teach yourself API coding
DarkOwl Announces Release of Ransomware API
Most commonly used HTTP Headers
Apiip Expand IP To Location API Services to Verify 1 million+ Requests A Month

Copyright © 2022 3v.org

Technologies, Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT